Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Locus and P&G collaborate on diabetes drug design

July 29, 2004

Enrollment completed in phase I/II study of GA-GCB for Gaucher's disease

July 29, 2004

APD-356 enters phase Ib study for obesity

July 29, 2004

Celera Genomics receives cathepsin K milestone from Merck

July 29, 2004

New glucokinase activators emerge from Roche R&D

July 29, 2004

Pfizer scientists design novel cannabinoid CB1 antagonists for obesity and alcohol and tobacco abuse

July 29, 2004

Results from six-month study of exenatide

July 28, 2004

Canadian NDS filing for GlucaGen

July 28, 2004

New glucagon receptor antagonists covered by Merck patent

July 28, 2004

AstraZeneca researchers prepare and test new PTP1B inhibitors

July 28, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...